1-7 of 7
Jean-Luc Van Laethem
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy

Claire Gallois, Julien Taieb, Delphine Le Corre, Karine Le Malicot, Josep Tabernero, Claire Mulot, Jean-François Seitz, Thomas Aparicio, Gunnar Folprecht, Côme Lepage, Enrico Mini, Jean-Luc Van Laethem, Jean-François Emile, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4745–4753.
https://doi.org/10.1158/1078-0432.CCR-18-0866
Published: 01 October 2018
View article titled, Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Open the PDF for Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

Raphaël Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svrcek, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Treut, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, Jean-Luc Van Laethem
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1215–1224.
https://doi.org/10.1158/1078-0432.CCR-14-0667
Published: 01 March 2015
View article titled, Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Open the PDF for Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Gilles Manceau, Sandrine Imbeaud, Raphaële Thiébaut, François Liébaert, Karine Fontaine, Francis Rousseau, Bérengère Génin, Delphine Le Corre, Audrey Didelot, Marc Vincent, Jean-Baptiste Bachet, Benoist Chibaudel, Olivier Bouché, Bruno Landi, Frédéric Bibeau, Karen Leroy, Frédérique Penault-Llorca, Jean-Luc Van Laethem, Pieter Demetter, Sabine Tejpar, Simona Rossi, Neda Mosakhani, Pia Österlund, Raija Ristamäki, Virinder Sarhadi, Sakari Knuutila, Valérie Boige, Thierry André, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (12): 3338–3347.
https://doi.org/10.1158/1078-0432.CCR-13-2750
Published: 12 June 2014
View article titled, Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Open the PDF for Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy in another window
Includes: Supplementary data
Journal Articles

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Eric Angevin, Josep Tabernero, Elena Elez, Steven J. Cohen, Rastilav Bahleda, Jean-Luc van Laethem, Christian Ottensmeier, Jose A. Lopez-Martin, Sally Clive, Florence Joly, Isabelle Ray-Coquard, Luc Dirix, Jean-Pascal Machiels, Neil Steven, Manjula Reddy, Brett Hall, Thomas A. Puchalski, Rajesh Bandekar, Helgi van de Velde, Brenda Tromp, Jessica Vermeulen, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2192–2204.
https://doi.org/10.1158/1078-0432.CCR-13-2200
Published: 15 April 2014
View article titled, A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Alex Parker, Salvatore Siena, Eric Van Cutsem, Jing Huang, Yves Humblet, Jean-Luc Van Laethem, Thierry André, Jeffrey Wiezorek, David Reese, Scott D. Patterson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1902–1912.
https://doi.org/10.1158/1078-0432.CCR-12-1913
Published: 02 April 2013
View article titled, Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Open the PDF for Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

Raphaël Maréchal, John R. Mackey, Raymond Lai, Pieter Demetter, Marc Peeters, Marc Polus, Carol E. Cass, James Young, Isabelle Salmon, Jacques Devière, Jean-Luc Van Laethem
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2913–2919.
https://doi.org/10.1158/1078-0432.CCR-08-2080
Published: 15 April 2009
View article titled, Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
Open the PDF for Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma in another window
Journal Articles

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5869–5876.
https://doi.org/10.1158/1078-0432.CCR-08-0449
Published: 14 September 2008
View article titled, Clinical Usefulness of <em>EGFR</em> Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent <em>In situ</em> Hybridization Study
Open the PDF for Clinical Usefulness of <em>EGFR</em> Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent <em>In situ</em> Hybridization Study in another window
Includes: Supplementary data